Emergent BioSolutions Inc. announced a contract modification valued at $56 million to supply ACAM2000 (Smallpox and Mpox (Vaccinia) Vaccine, Live) to the U.S. government. Deliveries under this modification are expected to commence in September 2025.
This award brings the total projected sales for ACAM2000 vaccine and ancillary products to more than $120 million this year from a diverse customer base. ACAM2000 is licensed for active immunization against both smallpox and mpox disease for individuals determined to be at high risk of infection.
The contract modification falls under Emergent’s existing 10-year contract with the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services. ACAM2000 was FDA approved in August 2024 for immunization against mpox, in addition to its existing smallpox indication.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.